Bhopal Newspaper

Lennox Gastaut Syndrome Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Lennox Gastaut Syndrome Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

November 14
22:50 2022
Lennox Gastaut Syndrome Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Delveinsight Business Research LLP
DelveInsight’s “Lennox Gastaut Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Lennox Gastaut Syndrome, historical and forecasted epidemiology as well as the Lennox Gastaut Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Lennox Gastaut Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Lennox Gastaut Syndrome, historical and forecasted epidemiology as well as the Lennox Gastaut Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Lennox Gastaut Syndrome market report provides current treatment practices, emerging drugs, Lennox Gastaut Syndrome market share of the individual therapies, and current and forecasted Lennox Gastaut Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Lennox Gastaut Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Lennox Gastaut Syndrome market.

Some of the key facts of the Lennox Gastaut Syndrome  Market Report:

  • Lennox-Gastaut syndrome can be caused by a variety of conditions, including brain malformations, tuberous sclerosis, perinatal asphyxia, severe head injury, central nervous system infection, and inherited genetic and inherited degenerative or metabolic conditions. In 30-35 percent of individuals, no cause can be found.

Key Benefits of the Lennox Gastaut Syndrome Market Report:

  • The report covers the descriptive overview of Lennox Gastaut Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

  • Comprehensive insight has been provided into the Lennox Gastaut Syndrome epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Lennox Gastaut Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of the Lennox Gastaut Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Lennox Gastaut Syndrome market

Got queries? Click here to learn more about the Lennox Gastaut Syndrome Market Landscape

Lennox Gastaut Syndrome Overview

Lennox-Gastaut syndrome is a severe form of epilepsy. Seizures begin in early childhood, usually before the age of 4 years. Children, adolescents, and adults with Lennox-Gastaut syndrome have multiple types of seizures that vary among individuals.

Lennox-Gastaut syndrome, epilepsy begins in early childhood, usually between ages 3 and 5. The most common seizure type is tonic seizures, which cause the muscles to stiffen (contract) uncontrollably. These seizures typically occur during sleep; they may also occur during wakefulness and cause sudden falls. Also common are atypical absence seizures, which cause a very brief partial or complete loss of consciousness. Additionally, many affected individuals have episodes called drop attacks, which cause sudden falls that can result in serious or life-threatening injuries. Drop attacks may be caused by the sudden loss of muscle tone (described as atonic) or by abnormal muscle contraction (described as tonic). Other types of seizures have been reported less frequently in people with Lennox-Gastaut syndrome. Seizures associated with Lennox-Gastaut syndrome often do not respond well to therapy with anti-epileptic medications.

People with Lennox-Gastaut syndrome have a higher risk of death than their peers of the same age. Although the increased risk is not fully understood, it is partly due to poorly controlled seizures and injuries from falls.

Lennox Gastaut Syndrome Epidemiological Insights:

  • Lennox-Gastaut syndrome is estimated to occur in. 1-. 28 people per 100,000 and is believed to account for 1-4 percent of all cases of childhood epilepsy. The annual incidence in children is estimated to be 2 per 100,000 children.

  • The  Lennox-Gastaut syndrome (LGS) incidence is estimated at 0.1 to 0.28 per 100,000 people per year, and the lifetime prevalence at the age of ten years amounts to 0.26 per 1000 children. Although rare, it represents 1-10% of childhood epilepsies and 1-2% of all epilepsy patients. Males are slightly more affected.

Lennox Gastaut Syndrome Epidemiological Segmentation 

  • Total Lennox Gastaut Syndrome prevalent cases 

  • Total Lennox Gastaut Syndrome diagnosed cases 

  • Total Lennox Gastaut Syndrome treated cases 

Lennox Gastaut Syndrome Market Outlook

 

The Lennox Gastaut Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Lennox Gastaut Syndrome market trends by analyzing the impact of current Lennox Gastaut Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Lennox Gastaut Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Lennox Gastaut Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Lennox Gastaut Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Lennox Gastaut Syndrome Market Trends

Lennox Gastaut Syndrome Key Companies

  • GlaxoSmithKline

  • Meda Pharmaceuticals

  • Roche

  • Lundbeck

  • Greenwich Biosciences

  • And many more 

 

Table of Contents

 

  1. Key Insights 

  2. Report Introduction 

  3. Executive Summary of Lennox Gastaut Syndrome  

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Lennox Gastaut Syndrome  Emerging Therapies

  7. Lennox Gastaut Syndrome  Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Appendix

  10. Lennox Gastaut Syndrome  Report Methodology

  11. DelveInsight Capabilities

  12. Disclaimer

  13. About DelveInsight

Click here to read more about  Lennox Gastaut Syndrome Market Report Offerings

 

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles